Cortecs International expects £50 million revenues from Helisal
This article was originally published in Clinica
An exclusive US distribution deal between Cortecs International and Boehringer Mannheim for Cortecs' doctors' office Helisal Rapid Blood tests for H pylori is expected to generate revenues of at least $24 million over the next six years. The 10-year agreement follows a similar £19 million deal signed earlier this year which excluded the US. Under this latest agreement Boehringer has the first right to negotiate for new Helisal products in the US and a right to improvements to the rapid blood test.